{"id":38113,"date":"2025-07-29T14:53:59","date_gmt":"2025-07-29T06:53:59","guid":{"rendered":"https:\/\/flcube.com\/?p=38113"},"modified":"2025-07-29T14:54:00","modified_gmt":"2025-07-29T06:54:00","slug":"fosun-pharma-secures-licensing-rights-for-ar1001-in-alzheimers-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38113","title":{"rendered":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#8217;s Treatment"},"content":{"rendered":"\n<p>China-based Fosun Pharmaceutical (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer&#8217;s disease (AD) and other neurological disorders.<\/p>\n\n\n\n<p><strong>AR1001: Mechanism and Potential<\/strong><br>AR1001 is an oral small molecule PDE5 inhibitor designed to slow the progression of Alzheimer&#8217;s disease. It acts as a potent and highly selective inhibitor of phosphodiesterase-5 (PDE-5). Preclinical and clinical studies suggest that AR1001 can clear amyloid plaques, inhibit abnormal Tau protein phosphorylation and inflammatory responses, and provide neuroprotective effects. Currently in a global multi-center Phase III clinical trial for early AD, AR1001 has demonstrated good blood-brain barrier permeability and safety. No drugs targeting this specific mechanism have been approved globally for AD treatment to date.<\/p>\n\n\n\n<p><strong>Financial and Strategic Terms<\/strong><br>Under the agreement, Fosun will make an upfront and regulatory milestone payment to Newco United Technology, not exceeding RMB 150 million. Additional payments will be based on sales milestones and tiered sales royalties from net sales of localized products. The agreement also includes supply arrangements, preferred negotiation rights, and provisions for future rights discussions in several Southeast Asian countries.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/600196_20250729_3UNG.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20250729_3UNG.\"><\/object><a id=\"wp-block-file--media-efe72734-d64c-49b0-b2ca-32bbe01a6e3d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/600196_20250729_3UNG.pdf\">600196_20250729_3UNG<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/600196_20250729_3UNG.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-efe72734-d64c-49b0-b2ca-32bbe01a6e3d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[159,1642,892],"class_list":["post-38113","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-fosun-pharmaceutical","tag-rehabilitative-geriatric-care","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#039;s Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer&#039;s disease (AD) and other neurological disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38113\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#039;s Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer&#039;s disease (AD) and other neurological disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38113\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-29T06:53:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-29T06:54:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#8217;s Treatment\",\"datePublished\":\"2025-07-29T06:53:59+00:00\",\"dateModified\":\"2025-07-29T06:54:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113\"},\"wordCount\":229,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2910.webp\",\"keywords\":[\"Fosun Pharmaceutical\",\"Rehabilitative \\\/ geriatric care\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38113#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38113\",\"name\":\"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2910.webp\",\"datePublished\":\"2025-07-29T06:53:59+00:00\",\"dateModified\":\"2025-07-29T06:54:00+00:00\",\"description\":\"China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer's disease (AD) and other neurological disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38113\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2910.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2910.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38113#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#8217;s Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer's disease (AD) and other neurological disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38113","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment","og_description":"China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer's disease (AD) and other neurological disorders.","og_url":"https:\/\/flcube.com\/?p=38113","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-29T06:53:59+00:00","article_modified_time":"2025-07-29T06:54:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38113#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38113"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#8217;s Treatment","datePublished":"2025-07-29T06:53:59+00:00","dateModified":"2025-07-29T06:54:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38113"},"wordCount":229,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38113#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp","keywords":["Fosun Pharmaceutical","Rehabilitative \/ geriatric care","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38113#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38113","url":"https:\/\/flcube.com\/?p=38113","name":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38113#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38113#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp","datePublished":"2025-07-29T06:53:59+00:00","dateModified":"2025-07-29T06:54:00+00:00","description":"China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a licensing agreement with Newco United Technology. This agreement grants Fosun Pharma exclusive rights to develop, register, manufacture, and commercialize the investigational drug AR1001 in mainland China, Hong Kong, and Macau. The licensed indications include Alzheimer's disease (AD) and other neurological disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38113#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38113"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38113#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp","width":1080,"height":608,"caption":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38113#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer&#8217;s Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2910.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38113"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38113\/revisions"}],"predecessor-version":[{"id":38116,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38113\/revisions\/38116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38115"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}